In Long-Awaited Guidance, FDA Lays Out Approval Path For Drugs And Companion Dxs

Draft document addresses how FDA expects drugs and devices to be developed contemporaneously and how those products will be reviewed simultaneously by the relevant regulatory centers at FDA with collaboration across divisions.